CD33 and acute myeloid leukemia: In this study, we show that ATCs armed with CD123Bi (CD123 BATs) or CD33GOBi (CD33GO BATs) exhibit high levels of specific cytotoxicity directed at CD123- and CD33-expressing cells, release Th1 cytokines/chemokines, and sensitize drug-resistant AML cells for chemo-responsiveness.